The pro-tumorigenic host response to cancer therapies

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Therapy resistance leads to tumor relapse and spread, a significant clinical challenge.
• Research has traditionally focused on tumor-intrinsic factors driving resistance.
• Emerging evidence highlights the crucial role of host responses in promoting cancer therapy resistance.

Purpose of the Study:

• To review recent advances in understanding host-mediated mechanisms of cancer therapy resistance.
• To focus on how cancer therapies can induce host responses that promote tumor progression.
• To explore the potential of host response evaluation in precision oncology.

Main Methods:

• Literature review of recent advances in cancer therapy resistance research.
• Analysis of host-mediated effects including immunological, angiogenic, and metastatic responses.
• Discussion of the implications for precision medicine.

Main Results:

• Cancer therapies can induce host responses that promote tumor microenvironment shifts.
• Host-mediated effects, including immunological, angiogenic, and metastatic changes, can facilitate tumor progression.
• Understanding these host responses is critical for overcoming therapy resistance.

Conclusions:

• Host responses significantly influence cancer therapy outcomes.
• Targeting host-mediated mechanisms presents a promising strategy to overcome resistance.
• Evaluating host responses is essential for advancing precision oncology.